The global "respules market" size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2022-2029).
A respule is a small plastic container with a liquid inside. The liquid is placed in a machine known as a nebulizer. The device turns the medicine into a fine mist, which the patient inhales through a face mask or mouthpiece.
Source: DataM Intelligence Analysis (2021)
The global respules market is expected to fuel due to different factors. The increasing advances in aerosol drug delivery systems are expected to drive market growth in the forecast period.
The increasing advances in aerosol drug delivery systems are expected to drive market growth in the forecast period.
Turbuhaler's devices hold up to 200 doses in a reservoir and deliver the medication twice as efficiently as pMDIs. The original Turbuhaler formulation with micronized drugs contains only the pure drug. In contrast, the active drug is blended with lactose particles in recent formulations, similar to the drug particles. There are various nebulizers, the most advanced of which deliver the formulation on a nano-scale. The advancement of nanotechnology and advanced forms of nebulization through liquid enable the delivery of these bright aerosolized particles, resulting in more brilliant drug carriers.
For instance, in terms of pharmacokinetic and safety studies, the device Pulmicort Respules (AstraZeneca) using the Pari LC jet nebulizer can be compared to nano-budesonide. Compared to Pulmicort Respules (4400 nm), nano budesonide have particle sizes ranging from 75 to 300 nm. The nano-budesonide allows for faster drug delivery, resulting in shorter nebulization times. On the other hand, Nanoparticles are more stable in the face of extreme forces generated during the nebulization process and prevent drug leakage. Nebulization devices are used to deliver drugs or formulations through the fine droplets in the bronchiolar region of the lungs.
The side effects associated with the use of nebulizer is expected to hamper the global respules market growth.
Individuals who use nebulizers may experience some side effects. Rapid heartbeat, jitteriness, and anxiety are the most common side effects of nebulizer treatment. Headache, nausea, vomiting, or throat irritation are less common side effects. Severe reactions to nebulizer treatment are also possible and should be reported to the prescribing physician as soon as possible. Chest pain, rash, hives, swelling, or difficulty swallowing are potentially dangerous symptoms. For instance, Duolin Respules may cause headaches, coughing, mouth dryness, nausea, constipation, and other side effects.
During COVID-19, many patients treated their respiratory conditions at home with a nebulizer. Because of the widespread shortage of Albuterol MDIs in the United States, prescribed more nebulizers to patients for albuterol use. According to researchers at the University of Oxford, early treatment with a commonly used asthma medication appeared to significantly reduce the need for urgent care and hospitalization in people with COVID-19. The STOIC study discovered that inhaled budesonide given to COVID-19 patients reduced recovery time within seven days of symptoms. Budesonide is a corticosteroid used to treat asthma and chronic obstructive pulmonary disease (COPD) in the long term (COPD). Hence, the demand for budesonide during COVID-19 is expected to positively impact the global respules market.
Based on drug type, budesonide is expected to dominate the market growth
Seasonal asthma has become the leading cause of climate and environmental change in respiratory ailments. Budesonide is used to treat and prevent asthma symptoms such as wheezing and shortness of breath. Budesonide is a corticosteroid, and it works directly on the lungs to make breathing easier by reducing airway irritation and swelling.
For instance, on November 13th, 2018, The U.S FDA approved Lupin's Budesonide Inhalation Suspension. It is the generic version of AstraZeneca's Pulmicort Respules Inhalation, i.e., Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampules. Budesonide is sold under the brand name Pulmicort. Pulmicort respules are only intended for inhalation via a compressed air-driven jet nebulizer. Budesonide is used to treat asthma symptoms such as difficulty breathing, chest tightness, wheezing, and coughing. Each budesonide inhaler is designed to provide 60 to 120 inhalations, depending on the size. Budesonide is a glucocorticoid used to treat asthma, various skin disorders, and allergic rhinitis. Budesonide is sold as a combination of two epimers (22R and 22S). Hence, the increased application of budesomide to treat different problems is expected to boost its market growth in the forecast period.
Global Respules Market - Geographical Analysis
North America region is expected to hold the largest market share in the global respules market.
The increasing prevalence of respiratory problems and FDA approvals is expected to fuel the market growth in this region.
According to the American College of Allergy, Asthma & Immunology, asthma affects approximately 25 million Americans. Equates to roughly one in every thirteen Americans, including 8% of adults and 7% of children. It affects about 20 million adults in the United States aged 18 and up. Adult women are more likely than adult men to suffer from asthma. The most used asthma medication is Albuterol. It's a quick-acting medication that provides almost immediate relief during an asthma attack. It can be administered using an inhaler or a nebulizer. Hence, the demand for Albuterol has boosted the FDA approvals for this medicine.
For instance, on April 08th, 2020, the U.S FDA approved the first generic version of Proventil HFA (albuterol sulfate) as a Metered Dose Inhaler, 90 mcg/Inhalation, for the treatment or prevention of bronchospasm in patients four years and older with reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group.
Source: DataM Intelligence Analysis (2021)
The global respules market is highly competitive with increasing demand, FDA approvals, company mergers. Some of the key players in the market are Cipla, AstraZeneca, Sandoz International GmbH, Biochemix Healthcare Private Limited, Lupin Limited, Amanta Healthcare, Lxir Medilabs Pvt. Ltd, Intra Life
Overview: Cipla Limited is headquartered in Mumbai, India. It is an Indian multinational pharmaceutical company. The company primarily develops medications to treat respiratory, cardiovascular, arthritis, diabetes, weight control, and depression, as well as other medical conditions.
Product Portfolio: The company's Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL are AN-rated generic equivalents of AstraZeneca's Pulmicort Respules and are indicated for the treatment of asthma and as prophylactic therapy in children aged 12 months to 8 years.
Critical Development: On November 17th, 2017, The U.S FDA approved Cipla company's Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension (0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL) to market a generic version of AstraZeneca's Pulmicort Respules.
The global respules market report would provide access to an approx. 45+ market data table, 40+ figures and 180 pages.
Get your free sample proposal with a single click!